57 results
Keyword Anoro Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Anoro Ellipta (previously Anoro)
umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 08/05/2014,
, Revision: 18, Authorised, Last updated: 22/11/2022
Anoro Ellipta (previously Anoro) Lung Diseases, Obstructive Lung … bromidevilanterol Overview Anoro Ellipta is a medicine used … to difficulty breathing. Anoro Ellipta is used for maintenance … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 February 2014
CHMP, Last updated: 21/02/2014Anoro … -
List item
National expert: Beate Mosl, Paul-Ehrlich-Institut (updated)
- Declaration of interests - 40.52 KB | PDF
- Curriculum Vitae - 23.79 KB | PDF
Research; Frankfurt; Germany Anoro COPD Past 01-01- 2015 01-01- 2018 Synexus … -
List item
Human medicine European public assessment report (EPAR): Laventair Ellipta (previously Laventair)
umeclidinium bromide, vilanterol, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 08/05/2014,, Revision: 17, Authorised, Last updated: 21/11/2022
-
List item
Human medicine European public assessment report (EPAR): Elebrato Ellipta
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017, Revision: 11, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Trelegy Ellipta
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017, Revision: 10, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Incruse Ellipta (previously Incruse)
umeclidinium bromide, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 28/04/2014,, Revision: 18, Authorised, Last updated: 15/11/2022
-
List item
Human medicine European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta)
umeclidinium bromide, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 20/03/2017,, Revision: 11, Authorised, Last updated: 21/11/2022
-
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 September 2023 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 11/09/2023 to 14/09/2023, Last updated: 14/09/2023 -
List item
List of medicines under additional monitoring
Last updated: 27/07/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 May 2023
European Medicines Agency, Amsterdam, the Netherlands, from 22/05/2023 to 25/05/2023, Last updated: 22/05/2023 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 25/09/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29 August - 1 September 2022
European Medicines Agency, Amsterdam, the Netherlands, from 29/08/2022 to 01/09/2022, Last updated: 02/09/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 July 2020
European Medicines Agency, Amsterdam, the Netherlands, from 06/07/2020 to 09/07/2020, Last updated: 10/12/2020 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 November 2014
European Medicines Agency, London, UK, from 03/11/2014 to 06/11/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 June 2015
European Medicines Agency, London, UK, from 08/06/2015 to 11/06/2015, Last updated: 13/03/2014 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 11/09/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-8 July 2016
European Medicines Agency, London, UK, from 04/07/2016 to 08/07/2016, Last updated: 04/07/2016 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 January 2017
European Medicines Agency, London, UK, from 09/01/2017 to 12/01/2017, Last updated: 13/03/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 February 2014
European Medicines Agency, London, UK, from 17/02/2014 to 20/02/2014, Last updated: 09/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 11-14 January 2016
European Medicines Agency, London, UK, from 11/01/2016 to 14/01/2016, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 24-27 October 2016
European Medicines Agency, London, UK, from 24/10/2016 to 27/10/2016, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 July 2017
European Medicines Agency, London, UK, from 03/07/2017 to 06/07/2017, Last updated: 13/03/2014